Core Viewpoint - dsm-firmenich is focusing on accelerating performance following its transformation into a fully consumer-focused company, with a strategic plan to enhance financial performance and operational efficiency [2][3]. Company Transformation - The company has completed its portfolio upgrade after divesting Animal Nutrition & Health, achieving €175 million in cost synergies and establishing a stronger foundation for future growth [2][3]. Strategic Focus - The priority for 2026-2027 is on execution to drive growth, expand EBITDA margins, and improve cash conversion, while maintaining disciplined capital allocation and normalizing capital expenditure [3][6]. Business Unit Updates - Key executives will provide updates on business fundamentals and action plans to drive growth and innovation across various business units, including Perfumery & Beauty, Health, Nutrition & Care, and Taste, Texture & Health [4]. Financial Outlook - The company anticipates cautious consumer demand and adverse foreign exchange effects to continue into 2026, with expectations for Continuing Operations to deliver specific financial targets [5][6]. Mid-term Targets - dsm-firmenich aims to achieve mid-term targets for Organic Sales Growth and Adjusted EBITDA margin by 2028, with an increased target for Adjusted Gross Operating Free Cash Flow from ≥10% to ≥14% [6]. Share Repurchase Program - A new share repurchase program has been announced, totaling €540 million, with €500 million aimed at reducing issued capital and €40 million for share-based compensation commitments [7]. Performance Metrics - The company projects organic sales growth of 2–4%, an Adjusted EBITDA margin around 20%, and a cash conversion rate of 11–12% for Adjusted Gross Operating Free Cash Flow to Sales [8].

Core Viewpoint - dsm-firmenich is focusing on accelerating performance following its transformation into a fully consumer-focused company, with a strategic plan to enhance financial performance and operational efficiency [2][3]. Company Overview - dsm-firmenich operates in nutrition, health, and beauty, with revenues exceeding €9 billion for its Continuing Operations after divesting Animal Nutrition & Health [9]. - The company has a global presence in nearly 60 countries and employs around 21,000 people [9]. Strategic Actions - The company has completed a portfolio upgrade and achieved €175 million in cost synergies from its merger integration, positioning itself for improved financial performance [2]. - A multi-lever plan is in place to drive growth, expand EBITDA margins, and enhance cash conversion, while maintaining disciplined capital allocation and normalizing capital expenditure [3]. Financial Outlook - For the full year 2026, dsm-firmenich anticipates cautious consumer demand and adverse foreign exchange effects to impact performance [5]. - The company aims to achieve mid-term targets for Organic Sales Growth and Adjusted EBITDA margin by 2028, with an increased target for Adjusted Gross Operating Free Cash Flow from ≥10% to ≥14% [6]. Share Repurchase Program - dsm-firmenich has announced a new share repurchase program totaling €540 million, with €500 million aimed at reducing issued capital and €40 million for share-based compensation commitments [7]. Performance Metrics - The company projects organic sales growth of 2–4%, an Adjusted EBITDA margin of around 20%, and a cash conversion rate of 11–12% for Adjusted Gross Operating Free Cash Flow to Sales [8].

Company Overview - Averin Capital Acquisition Corp. is a blank check company formed to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily focusing on opportunities in the technology and health industries [2]. IPO Details - The company announced the pricing of its initial public offering (IPO) of 25,000,000 units at a price of $10.00 per unit, with units expected to be listed on the Nasdaq Global Market under the ticker symbol "ACAAU" starting February 19, 2026 [1]. - Each unit consists of one Class A ordinary share and one-sixth of one redeemable warrant, with each whole warrant allowing the holder to purchase one Class A ordinary share at a price of $11.50 per share [1]. - An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering, which is expected to close on February 20, 2026, subject to customary closing conditions [1]. - The underwriters have been granted a 45-day option to purchase up to an additional 3,750,000 units at the initial public offering price to cover over-allotments [1]. Management Team - The management team is led by David A. Berry as Chairman and Chief Executive Officer, and Alex Lau as Chief Financial Officer and Secretary. The Board of Directors includes Ulrik Schulze, Graeme Bell, and Mary T. Szela [3]. Underwriting - Deutsche Bank Securities Inc. is acting as the sole book-running manager for the offering [3]. Regulatory Information - A registration statement relating to the securities has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on February 18, 2026 [5]. - The offering is being made only by means of a prospectus, which can be obtained from Deutsche Bank Securities Inc. or accessed via the SEC's website [4].

Core Insights - Nu Skin Enterprises reported fourth quarter and full-year 2025 results within guidance, achieving over 50% growth in earnings for the year [1] - The company anticipates a return to revenue growth by the end of 2026, driven by the global launch of Prysm iO intelligent wellness devices [1] Financial Performance - Q4 2025 revenue was $370.3 million, a decrease of 16.9% year-over-year, or 10.4% excluding Mavely revenue [1] - Full-year 2025 revenue totaled $1.49 billion, down 14.3% from 2024, or 10.7% excluding Mavely revenue [1] - Earnings per share (EPS) for Q4 2025 was $0.29, compared to a loss of $(0.73) in Q4 2024, or $0.38 excluding restructuring and other charges [1] - Full-year EPS for 2025 was $3.18, compared to $(2.95) in 2024, or $1.27 excluding Mavely gain and other charges [1] Customer and Affiliate Metrics - The total number of customers decreased by 10% to 748,796 in Q4 2025 compared to the previous year [1] - Paid affiliates decreased by 11% to 129,311, while sales leaders fell by 19% to 30,045 [1] Segment Performance - Revenue by region for Q4 2025 showed declines across all major markets, with the Americas down 9.8%, Southeast Asia/Pacific down 22.7%, and Mainland China down 7.8% [3] - For the full year 2025, revenue in the Americas decreased by 12.3%, Southeast Asia/Pacific by 14.3%, and Mainland China by 16.9% [3] Outlook for 2026 - Q1 2026 revenue is projected to be between $320 million and $340 million, reflecting a decline of 12% to 7% [1] - Full-year 2026 revenue is expected to range from $1.35 billion to $1.50 billion, with an EPS forecast of $0.80 to $1.20 [1] Strategic Initiatives - The company is focusing on aligning sales leaders around the launch of Prysm iO, with over 20,000 devices already distributed [1] - Pre-market activities in India are underway, with a full market opening anticipated in the latter half of 2026 [1]

Core Insights - Tenet Healthcare Corporation reported strong financial results for the fourth quarter and full year 2025, with a net income of $371 million or $4.22 per diluted share in Q4 2025, reflecting a 16.7% increase from Q4 2024 [1][2] - Adjusted diluted earnings per share rose 36.6% to $4.70 in Q4 2025 compared to $3.44 in Q4 2024, driven by robust revenue growth and disciplined expense management [1][2] - The company anticipates FY 2026 Adjusted EBITDA to be between $4.485 billion and $4.785 billion, indicating continued growth expectations [1][2] Financial Performance - Q4 2025 net operating revenues reached $5.527 billion, up 8.9% from $5.073 billion in Q4 2024, while FY 2025 revenues totaled $21.310 billion, a 3.1% increase from $20.675 billion in FY 2024 [1][5] - Consolidated Adjusted EBITDA for Q4 2025 was $1.183 billion, a 12.9% increase from $1.048 billion in Q4 2024, with an Adjusted EBITDA margin of 21.4% [1][2] - The company generated free cash flow of $2.53 billion in FY 2025, compared to $1.116 billion in FY 2024, highlighting improved cash generation capabilities [1][5] Segment Performance - The Ambulatory Care segment reported Q4 2025 net operating revenues of $1.433 billion, a 13.8% increase from $1.259 billion in Q4 2024, driven by strong same-facility net patient service revenues [2][6] - The Hospital Operations segment saw Q4 2025 net operating revenues of $4.094 billion, a 7.3% increase from $3.814 billion in Q4 2024, attributed to favorable payer mix and higher acuity services [2][6] - Adjusted EBITDA for the Ambulatory segment was $580 million in Q4 2025, up 9.4% from $530 million in Q4 2024, while the Hospital segment's Adjusted EBITDA increased to $603 million from $518 million in the same period [2][6] Balance Sheet and Cash Flow - Cash flows from operating activities for FY 2025 were $3.54 billion, significantly higher than $2.047 billion in FY 2024, reflecting improved operational efficiency [1][5] - The company repurchased 8.8 million shares for $1.386 billion in FY 2025, indicating a commitment to returning value to shareholders [1][5] - As of December 31, 2025, the ratio of net debt to Adjusted EBITDA was 2.25x, down from 2.54x a year earlier, indicating improved leverage [1][5] 2026 Financial Outlook - For FY 2026, Tenet expects net operating revenues to be between $21.500 billion and $22.300 billion, with net income available to common stockholders projected between $2.605 billion and $2.840 billion [2][6] - The company anticipates Adjusted EBITDA margins to range from 20.9% to 21.5% in FY 2026, reflecting continued operational improvements [2][6] - The Ambulatory segment is expected to see net operating revenues of $5.500 billion to $5.700 billion, while the Hospital segment is projected to generate $16.000 billion to $16.600 billion in revenues [2][6]

DSM says it will divest its animal nutrition and health business to CVC Capital Partners for an enterprise value of about $2.6 billion https://t.co/SLuhJDHkz2 ...

Core Viewpoint - dsm-firmenich has agreed to divest its Animal Nutrition & Health (ANH) business to CVC Capital Partners for an enterprise value of approximately €2.2 billion, which includes an earnout of up to €0.5 billion, while retaining a 20% equity stake in the divested companies [1][2]. Group 1: Transaction Details - The divestment of ANH follows the sale of Feed Enzymes activities to Novonesis for €1.5 billion in 2025, marking a strategic shift for dsm-firmenich to focus solely on consumer sectors in nutrition, health, and beauty [2]. - The total enterprise value of ANH, including the previous sale, amounts to €3.7 billion, reflecting a 10x EV/Adjusted EBITDA multiple [2][5]. - dsm-firmenich expects to receive approximately €1.2 billion post-transaction, with an estimated €0.6 billion in net cash proceeds and a vendor loan note of €0.1 billion [5][12]. Group 2: Business Structure and Operations - ANH will be divided into two standalone companies: the "Solutions Company" and the "Essential Products Company," both based in Kaiseraugst, Switzerland [5]. - The Solutions Company will focus on Performance Solutions, Premix, and Precision Services, while the Essential Products Company will handle Vitamins, Carotenoids, and Aroma Ingredients [5]. - dsm-firmenich will enter into a long-term supply agreement for vitamins with the Essential Products Company to ensure continuity in supply for human and pet food applications [5]. Group 3: Financial and Strategic Implications - The transaction is expected to result in a non-cash impairment of around €1.9 billion in 2025 before taxes, with additional cash tax and transaction costs of €0.2 billion anticipated in 2026 [12]. - dsm-firmenich plans to initiate a share repurchase program worth €0.5 billion in Q1 2026 and aims to maintain a stable dividend of €2.50 per share, with a policy of progressively increasing dividends over time [3][4]. - The CEO of dsm-firmenich emphasized that this divestment represents the final step in their strategic roadmap, aiming to accelerate growth and create long-term value for stakeholders [7].

Fitbit founders launch AI platform to help families monitor their health https://t.co/Etmg6HcDm8 ...

Core Insights - Tmall International is set to welcome 2,415 new overseas brands in 2025, indicating a double-digit growth in the number of first stores opened, averaging over 6 new brands daily [1][3] - The top three new imported brands for 2025 include the South Korean fashion brand COVERNAT, the Australian nutrition brand herbs of gold, and the South Korean celebrity merchandise brand Weverse Shop [1][3] - The new brands span 52 countries and regions, with the highest number coming from the United States, Japan, and South Korea, while France, New Zealand, and Australia show the fastest growth [1][3] Industry Trends - The most concentrated influx of new overseas brands is in the health, beauty, and maternal and infant sectors, with the maternal and infant industry seeing a 128% increase in new brands, particularly in the baby food segment [1][3] - The fastest-growing categories in terms of transaction volume over the past year include toys, outdoor equipment, baby food, fashion cosmetics, and pet health, all of which have doubled in growth, reflecting consumer preferences for quality imports and family-oriented products [1][3] Brand Expansion - Tmall International currently hosts over 40,000 brands from more than 110 countries and regions, indicating a significant global reach and brand diversity [2][4]

Fertility startup Inito wants to use AI-designed antibodies to expand at-home health tests https://t.co/03debIl0nO ...